Evidence map›Paper›PMID 26055363›Full record

ArticleAntimicrobial agents and chemotherapy2015

Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.

Claudia Alteri, Matteo Surdo, Maria Concetta Bellocchi, Patrizia Saccomandi, Fabio Continenza, Daniele Armenia, Lucia Parrotta, Luca Carioti, Giosuè Costa, Slim Fourati and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular Biology and Diversification of Human Retroviruses.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Claudia AlteriUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Matteo SurdoUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Maria Concetta BellocchiUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Patrizia SaccomandiUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Fabio ContinenzaINMI L. Spallanzani, Rome, Italy.
Daniele ArmeniaUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Lucia ParrottaUniversità Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Campus Universitario, Catanzaro, Italy.
Luca CariotiUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Giosuè CostaUniversità Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Campus Universitario, Catanzaro, Italy.
Slim FouratiDepartment of Virology, Hospital "Pitie Salpietrere," Paris, France.
Fabiola Di SantoUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Rossana ScutariUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Silvia BarbalisciaUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Valentina FedeleINMI L. Spallanzani, Rome, Italy.
Stefania CartaINMI L. Spallanzani, Rome, Italy.
Emanuela BalestraUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Stefano AlcaroUniversità Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Campus Universitario, Catanzaro, Italy.
Anne Genevieve MarcelinDepartment of Virology, Hospital "Pitie Salpietrere," Paris, France.
Vincent CalvezDepartment of Virology, Hospital "Pitie Salpietrere," Paris, France.
Francesca Ceccherini-SilbersteinUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy.
Anna ArteseUniversità Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Campus Universitario, Catanzaro, Italy.
Carlo Federico PernoUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy INMI L. Spallanzani, Rome, Italy valentina.svicher@uniroma2.it cf.perno@uniroma2.it.
Valentina SvicherUniversity of Rome "Tor Vergata," Department of Experimental Medicine and Surgery, Rome, Italy valentina.svicher@uniroma2.it cf.perno@uniroma2.it.
University of Rome Tor Vergata · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITMagna Graecia University · ITDepartment of Virology · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incomplete APOBEC3G/F neutralization by a defective HIV-1Vif protein can promote genetic diversification by inducing G-to-A mutations in the HIV-1 genome. The HIV-1 Env V3 loop, critical for coreceptor usage, contains several putative APOBEC3G/F target sites. Here, we determined if APOBEC3G/F, in the presence of Vif-defective HIV-1 virus, can induce G-to-A mutations at V3 positions critical to modulation of CXCR4 usage. Peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM) from 2 HIV-1-negative donors were infected with CCR5-using 81.A-VifWT virus (i.e., with wild-type [WT] Vif protein), 81.A-VifE45G, or 81.A-VifK22E (known to incompletely/partially neutralize APOBEC3G/F). The rate of G-toA mutations was zero or extremely low in 81.A-VifWT- and 81.A-VifE45G-infected PBMC from both donors. Conversely, G-to-A enrichment was detected in 81.A-VifK22E-infected PBMC (prevalence ranging from 2.18% at 7 days postinfection [dpi] to 3.07% at 21 dpi in donor 1 and from 10.49% at 7 dpi to 8.69% at 21 dpi in donor 2). A similar scenario was found in MDM. G-to-A mutations occurred at 8 V3 positions, resulting in nonsynonymous amino acid substitutions. Of them, G24E and E25K strongly correlated with phenotypically/genotypically defined CXCR4-using viruses (P = 0.04 and 5.5e-7, respectively) and increased the CXCR4 N-terminal binding affinity for V3 (WT, -40.1 kcal/mol; G24E, -510 kcal/mol; E25K, -522 kcal/mol). The analysis of paired V3 and Vif DNA sequences from 84 HIV-1-infected patients showed that the presence of a Vif-defective virus correlated with CXCR4 usage in proviral DNA (P = 0.04). In conclusion, incomplete APOBEC3G/F neutralization by a single Vif amino acid substitution seeds a CXCR4-using proviral reservoir. This can have implications for the success of CCR5 antagonist-based therapy, as well as for the risk of disease progression.

Indexed as

Amino Acid SequenceAmino Acid SubstitutionAPOBEC DeaminasesBase SequenceCell LineCytidine DeaminaseCytosine DeaminaseEvolution, MolecularHEK293 CellsHIV-1HIV InfectionsHumansLeukocytes, MononuclearMutationReceptors, CCR5Receptors, CXCR4APOBEC3 proteins, humanAPOBEC DeaminasesCCR5 protein, humanCXCR4 protein, humanCytidine DeaminaseCytosine DeaminaseReceptors, CCR5Receptors, CXCR4

Identifiers

PMID26055363
PMCPMC4505216
OpenAlexW2116211494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.